Ipamorelin

Mechanism of Action

Ipamorelin is a synthetic pentapeptide that acts as a selective growth hormone secretagogue by binding to the ghrelin/GHS-R1a receptor on pituitary somatotroph cells. This binding triggers intracellular signaling cascades that stimulate the release of growth hormone (GH) from the pituitary gland. Unlike other GH secretagogues such as GHRP-6, ipamorelin demonstrates unique selectivity by potently releasing GH without significantly affecting ACTH or cortisol levels. Key Pathways: Ghrelin/GHS-R1a receptor activation on pituitary somatotrophs, Growth hormone release and downstream GH/IGF-1 axis signaling, Potential ghrelin-mediated gastric pathway involvement By selectively stimulating GH release without triggering cortisol or ACTH elevation, ipamorelin may support muscle growth, bone formation, and recovery while minimizing stress hormone-related side effects. Animal studies demonstrate dose-dependent increases in longitudinal bone growth, body weight gain, and counteraction of glucocorticoid-induced bone loss, suggesting relevance to recovery and anti-aging applications.

Common Dose Reference Ranges

Educational reference ranges only — discuss actual dosing with a qualified healthcare provider.

Full Ipamorelin protocols — frequency, timing, cycle length, reconstitution & research